A familial insulin-like growth factor-I receptor mutant leads to short stature: Clinical and biochemical characterization

Kenjiro Inagaki, Anatoly Tiulpakov, Petr Rubtsov, Polina Sverdlova, Valentina Peterkova, Shoshana Yakar, Sergei Terekhov, Derek LeRoith

Research output: Contribution to journalArticle

Abstract

Context: IGF-I/IGF-I receptor (IGF-IR) signaling pathways play important roles in longitudinal growth. A novel Arg481Glu (R481Q) mutation in IGF-IR was detected in a family with intrauterine and postnatal growth retardation. Objective: The objective of the study was to explore the mechanism whereby the R481Q mutation may be causative in growth retardation. Patients: A 13-yr-old girl with short stature was studied for functional analysis of the R481Q mutation in the IGF-IR. Results: Two members of a family who showed intrauterine and postnatal growth retardation, with increased serum IGF-I levels, demonstrated a substitution of arginine for glutamine at 481 (R481Q) in the IGF-IR. This mutation results in the formation of an altered fibronectin type III domain within the α-subunit. NIH-3T3 fibroblasts that overexpress the human wild-type or R481Q mutant IGF-IR demonstrated normal cell surface ligand binding by 125I-IGF-I binding assay. However, the fold increase of IGF-I stimulated tyrosine phosphorylation of the IGF-IR β-subunit as well as downstream activation of ERK1/2 and Akt was reduced in cells overexpressing the mutant receptor. Additionally, basal and IGF-I-stimulated levels of cell proliferation were also reduced in cells overexpressing the mutant receptor. Conclusion: Our results demonstrate that NIH-3T3 cells overexpressing a mutant form of the Igf1r gene, in which arginine at 481 is substituted by glutamine, lead to reduced levels of the fold increase of IGF-IR β-subunit phosphorylation as well as ERK1/2 and Akt phosphorylation and was accompanied by decreased cell proliferation. These results are postulated to be the cause of intrauterine and postnatal growth retardation in the described patients.

Original languageEnglish (US)
Pages (from-to)1542-1548
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume92
Issue number4
DOIs
StatePublished - Apr 2007

Fingerprint

IGF Type 1 Receptor
Insulin-Like Growth Factor I
Phosphorylation
Fetal Growth Retardation
Mutation
Cell proliferation
Glutamine
Arginine
Cell Proliferation
NIH 3T3 Cells
Functional analysis
Fibroblasts
Growth
Fibronectins
Tyrosine
Assays
Substitution reactions
Genes
Chemical activation
Ligands

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

A familial insulin-like growth factor-I receptor mutant leads to short stature : Clinical and biochemical characterization. / Inagaki, Kenjiro; Tiulpakov, Anatoly; Rubtsov, Petr; Sverdlova, Polina; Peterkova, Valentina; Yakar, Shoshana; Terekhov, Sergei; LeRoith, Derek.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 92, No. 4, 04.2007, p. 1542-1548.

Research output: Contribution to journalArticle

Inagaki, Kenjiro ; Tiulpakov, Anatoly ; Rubtsov, Petr ; Sverdlova, Polina ; Peterkova, Valentina ; Yakar, Shoshana ; Terekhov, Sergei ; LeRoith, Derek. / A familial insulin-like growth factor-I receptor mutant leads to short stature : Clinical and biochemical characterization. In: Journal of Clinical Endocrinology and Metabolism. 2007 ; Vol. 92, No. 4. pp. 1542-1548.
@article{13bdb3715dea4dc4bba9325d51e28165,
title = "A familial insulin-like growth factor-I receptor mutant leads to short stature: Clinical and biochemical characterization",
abstract = "Context: IGF-I/IGF-I receptor (IGF-IR) signaling pathways play important roles in longitudinal growth. A novel Arg481Glu (R481Q) mutation in IGF-IR was detected in a family with intrauterine and postnatal growth retardation. Objective: The objective of the study was to explore the mechanism whereby the R481Q mutation may be causative in growth retardation. Patients: A 13-yr-old girl with short stature was studied for functional analysis of the R481Q mutation in the IGF-IR. Results: Two members of a family who showed intrauterine and postnatal growth retardation, with increased serum IGF-I levels, demonstrated a substitution of arginine for glutamine at 481 (R481Q) in the IGF-IR. This mutation results in the formation of an altered fibronectin type III domain within the α-subunit. NIH-3T3 fibroblasts that overexpress the human wild-type or R481Q mutant IGF-IR demonstrated normal cell surface ligand binding by 125I-IGF-I binding assay. However, the fold increase of IGF-I stimulated tyrosine phosphorylation of the IGF-IR β-subunit as well as downstream activation of ERK1/2 and Akt was reduced in cells overexpressing the mutant receptor. Additionally, basal and IGF-I-stimulated levels of cell proliferation were also reduced in cells overexpressing the mutant receptor. Conclusion: Our results demonstrate that NIH-3T3 cells overexpressing a mutant form of the Igf1r gene, in which arginine at 481 is substituted by glutamine, lead to reduced levels of the fold increase of IGF-IR β-subunit phosphorylation as well as ERK1/2 and Akt phosphorylation and was accompanied by decreased cell proliferation. These results are postulated to be the cause of intrauterine and postnatal growth retardation in the described patients.",
author = "Kenjiro Inagaki and Anatoly Tiulpakov and Petr Rubtsov and Polina Sverdlova and Valentina Peterkova and Shoshana Yakar and Sergei Terekhov and Derek LeRoith",
year = "2007",
month = "4",
doi = "10.1210/jc.2006-2354",
language = "English (US)",
volume = "92",
pages = "1542--1548",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - A familial insulin-like growth factor-I receptor mutant leads to short stature

T2 - Clinical and biochemical characterization

AU - Inagaki, Kenjiro

AU - Tiulpakov, Anatoly

AU - Rubtsov, Petr

AU - Sverdlova, Polina

AU - Peterkova, Valentina

AU - Yakar, Shoshana

AU - Terekhov, Sergei

AU - LeRoith, Derek

PY - 2007/4

Y1 - 2007/4

N2 - Context: IGF-I/IGF-I receptor (IGF-IR) signaling pathways play important roles in longitudinal growth. A novel Arg481Glu (R481Q) mutation in IGF-IR was detected in a family with intrauterine and postnatal growth retardation. Objective: The objective of the study was to explore the mechanism whereby the R481Q mutation may be causative in growth retardation. Patients: A 13-yr-old girl with short stature was studied for functional analysis of the R481Q mutation in the IGF-IR. Results: Two members of a family who showed intrauterine and postnatal growth retardation, with increased serum IGF-I levels, demonstrated a substitution of arginine for glutamine at 481 (R481Q) in the IGF-IR. This mutation results in the formation of an altered fibronectin type III domain within the α-subunit. NIH-3T3 fibroblasts that overexpress the human wild-type or R481Q mutant IGF-IR demonstrated normal cell surface ligand binding by 125I-IGF-I binding assay. However, the fold increase of IGF-I stimulated tyrosine phosphorylation of the IGF-IR β-subunit as well as downstream activation of ERK1/2 and Akt was reduced in cells overexpressing the mutant receptor. Additionally, basal and IGF-I-stimulated levels of cell proliferation were also reduced in cells overexpressing the mutant receptor. Conclusion: Our results demonstrate that NIH-3T3 cells overexpressing a mutant form of the Igf1r gene, in which arginine at 481 is substituted by glutamine, lead to reduced levels of the fold increase of IGF-IR β-subunit phosphorylation as well as ERK1/2 and Akt phosphorylation and was accompanied by decreased cell proliferation. These results are postulated to be the cause of intrauterine and postnatal growth retardation in the described patients.

AB - Context: IGF-I/IGF-I receptor (IGF-IR) signaling pathways play important roles in longitudinal growth. A novel Arg481Glu (R481Q) mutation in IGF-IR was detected in a family with intrauterine and postnatal growth retardation. Objective: The objective of the study was to explore the mechanism whereby the R481Q mutation may be causative in growth retardation. Patients: A 13-yr-old girl with short stature was studied for functional analysis of the R481Q mutation in the IGF-IR. Results: Two members of a family who showed intrauterine and postnatal growth retardation, with increased serum IGF-I levels, demonstrated a substitution of arginine for glutamine at 481 (R481Q) in the IGF-IR. This mutation results in the formation of an altered fibronectin type III domain within the α-subunit. NIH-3T3 fibroblasts that overexpress the human wild-type or R481Q mutant IGF-IR demonstrated normal cell surface ligand binding by 125I-IGF-I binding assay. However, the fold increase of IGF-I stimulated tyrosine phosphorylation of the IGF-IR β-subunit as well as downstream activation of ERK1/2 and Akt was reduced in cells overexpressing the mutant receptor. Additionally, basal and IGF-I-stimulated levels of cell proliferation were also reduced in cells overexpressing the mutant receptor. Conclusion: Our results demonstrate that NIH-3T3 cells overexpressing a mutant form of the Igf1r gene, in which arginine at 481 is substituted by glutamine, lead to reduced levels of the fold increase of IGF-IR β-subunit phosphorylation as well as ERK1/2 and Akt phosphorylation and was accompanied by decreased cell proliferation. These results are postulated to be the cause of intrauterine and postnatal growth retardation in the described patients.

UR - http://www.scopus.com/inward/record.url?scp=34147115812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147115812&partnerID=8YFLogxK

U2 - 10.1210/jc.2006-2354

DO - 10.1210/jc.2006-2354

M3 - Article

VL - 92

SP - 1542

EP - 1548

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -